NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD

Novo Nordisk A/S

Novo Allé
Bagsvaerd 2880
45 44 44 88 88

IndustryDrug Manufacturers - Other
Full Time Employees42,076

Key Executives

Mr. Lars Fruergaard J�rgensenPres & CEON/AN/A51
Mr. Jesper BrandgaardExec. VP of Biopharma & Legal AffairsN/AN/A54
Dr. Mads Krogsgaard ThomsenExec. VP & Chief Science OfficerN/AN/A57
Ms. Liselotte HyveledDirector116.58kN/A51
Mr. Karsten Munk KnudsenExec. VP & CFON/AN/A45
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/S’s ISS Governance QualityScore as of February 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.